# RFT-5-dgA in Patients With Metastatic Melanoma

> **NCT00314093** · PHASE2 · COMPLETED · sponsor: **University of Texas Southwestern Medical Center** · enrollment: 41 (actual)

## Conditions studied

- Metastatic Melanoma

## Interventions

- **DRUG:** RFT5pdgA

## Key facts

- **NCT ID:** NCT00314093
- **Lead sponsor:** University of Texas Southwestern Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-04
- **Primary completion:** 2008-11
- **Final completion:** 2008-11
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2019-11-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00314093

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00314093, "RFT-5-dgA in Patients With Metastatic Melanoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00314093. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*